Document › Details
PeptiDream Inc.. (4/29/15). "Press Release: PeptiDream Announces Peptide Discovery Collaboration Agreement with Merck & Co., Inc". Tokyo.
|Organisation||PeptiDream Inc. (JP)|
|Organisation 2||Merck & Co. Inc. (NYSE: MRK)|
|Group||Merck (US) (Group)|
|Product||Peptide Discovery Platform System (PDPS) technology|
|Product 2||peptide-based drug|
|Person||Kubota, Kiichi (PeptiDream 201504 CEO)|
PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”) (Tokyo:4587) today announced a multi-target discovery and optimization collaboration with Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, through a subsidiary. Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocylic/constrained peptides against multiple targets of interest selected by Merck & Co. Inc. Merck & Co. Inc. will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration and retains an option to nonexclusively license the PDPS technology at a future date. PeptiDream will receive an undisclosed upfront payment, research funding and will be eligible for payments associated with the achievement of certain preclinical and clinical development milestones. In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration.
“We are very excited to collaborate with Merck & Co. Inc. PeptiDream has emerged as a major player in the constrained peptide space, said Kiichi Kubota, CEO of PeptiDream Inc. Our unique PDPS platform allows us to rapidly build highly diverse constrained peptide libraries, largely tailored to the individual target, leading to the rapid identification of chemically diverse hits, which can then be quickly assessed for the desired biological activity profiles. No other technology can create such a chemically and structurally diverse set of functional and developable leads in such a short period of time”.
In the past five years, PeptiDream has established funded discovery collaborations with many leading pharmaceutical companies, such as Amgen, AstraZeneca, Bristol-Myers-Squibb, Eli Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, as well as a strategic collaboration with Ipsen, all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb and Novartis.
(Ticker Code:4587 TSE Mothers)
<About PeptiDream Inc.>
PeptiDream Inc. is a public (Tokyo Stock Exchange Mothers 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS) , a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics. PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide. For further information please visit www.peptidream.com
Patrick C Reid +81-3-5790-9991 (Tokyo)
Record changed: 2017-04-02
More documents for PeptiDream Inc. (JP)
-  PeptiDream Inc.. (4/2/15). "Press Release: PeptiDream Announces License of PeptiDream’s Peptide Discovery Platform System (PDPS) Technology to Novartis". Tokyo....
To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to firstname.lastname@example.org and simply fill the subject line with the word »LSG newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)